| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8dc1442e8263a086103a8b2a6b9753f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e473613f549ad747f3af840e73fac8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-02 |
| filingDate |
2018-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f11084499358f9535675e3e729829b40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_163306589b571f9f5393e4acd27d6f55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_941e1b5639cdd7c0a1f2b30796ca4881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bf3b874e4ab2ea6d74139438d4b27b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fdd6c51e427f15b2b3ecfda96cfe13b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d0a70cb8a152f2964c91cb5a5524701
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d01445d8514ce0d41ae104a6c6b16c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4902032fd554ab8b0e950ce99d18c090 |
| publicationDate |
2020-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3727446-A1 |
| titleOfInvention |
Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
| abstract |
Provided herein are Modified Vaccinia Ankara (MVA) vectors and adenovirus vectors encoding HBV antigens. Also provided are methods of enhancing an immune response in a human subject by utilizing the MVA and adenovirus vectors encoding HBV antigens in a prime/boost regimen to the enhance the immune response in the human subject. |
| priorityDate |
2017-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |